Yael Haberman Ziv, MD, PhD

Supplementation with endogenous healthy gut metabolites reverses the disruptions of in vitro and ex vivo epithelial functions induced by fecal content from IBD patients. Abbas-Egbariya, H; Elwahidi, L; Levy, DJ; Braun, T; Levhar, N; Hadar, R; Efroni, G; Granot, M; Leichtmann-Bardogoo, Y; Maoz, BM; Ben-Horin, S; Vandussen, KL; Amir, A; Haberman, Y. Gut Microbes. 2025; 17(1):2597568.

Short Ileal Microvillus Length Phenotype Associates with Progression from Inflammatory to Complicated Disease Behavior in Pediatric Crohn's Disease. Haberman, Y; Braun, T; Karns, R; Bartel, CA; Bonkowski, E; Simpson, KF; Walters, TD; Hyams, JS; Liu, T-C; Kugathasan, S; Denson, LA; Vandussen, KL. Inflammatory Bowel Diseases. 2025.

Elderly-Onset Inflammatory Bowel Disease Has Distinct Disease Characteristics and Treatment Patterns. Granot, M; Kopylov, U; Talmor, Y; Nachum, N; Krauthammer, A; Berger, T; Abitbol, CM; Dotan, A; Borenstein, E; Ben-Horin, S; Weiss, B; Haberman, Y. United European Gastroenterology Journal. 2025; 13(9):1754-1764.

Overcoming anti-Infliximab antibodies and maintaining Infliximab achieves superior durability and outcome compared to switching to Adalimumab. Granot, M; Nachum, N; Krauthammer, A; Berger, TD; Heiman, S; Yavzori, M; Picard, O; Ben-Horin, S; Weiss, B; Haberman, Y. Digestive and Liver Disease. 2025; 57(11):2128-2134.

Fecal and Serum Metabolome in Crohn's Disease is Linked With Future Flare. Levhar, N; Hadar, R; Braun, T; Naamneh, R; Efroni, G; Agranovich, B; Abramovich, I; Asher, AT; Picard, O; Lahat, A; Eliakim, R; Ben-Horin, S; Amir, A; Haberman, Y. United European Gastroenterology Journal. 2025; 13(7):1278-1288.

Capsule Endoscopy-Guided Proactive Treat-to-Target Versus Continued Standard Care in Patients With Quiescent Crohn's Disease: A Randomized Controlled Trial. Ben-Horin, S; Lahat, A; Ungar, B; Ukashi, O; Yablecovitch, D; Amitai, MM; Haberman, Y; Selinger, L; Talan-Asher, A; Kriger-Sharabi, O; Yanai, H; Dotan, I; Kopylov, U; Eliakim, R. Gastroenterology. 2025; 169(1):85-93.e3.

Baseline terminal ileal CT and MRI measurements are associated with imaging outcomes in pediatric Crohn's disease: a cohort study. Ta, AD; Dillman, JR; Ollberding, NJ; Haberman, Y; Baldassano, R; Markowitz, J; Otley, A; Dotson, JL; Pfefferkorn, M; Hyams, JS; Snapper, S; Alazraki, A; Kugathasan, S; Denson, LA. Pediatric Radiology. 2025; 55(8):1642-1651.

Expert recommendations to standardize transcriptomic analysis in inflammatory bowel disease clinical trials. Linggi, B; Azucena, S; Steere, B; Verstockt, B; Alsoud, D; Casero, D; Mcgovern, D; Chan, E; Smith, MI; Ungaro, F; Haberman, Y; Feagan, BG; Jairath, V; Vande Casteele, N. Journal of Crohn's and Colitis. 2025; 19(5).

1033: ENHANCING GUT EPITHELIAL INTEGRITY AND REDUCING EPITHELIAL INFLAMMATION THROUGH SUPPLEMENTATION OF FECAL METABOLITES, GUIDED BY NOVEL EX VIVO FUNCTIONAL PRIORITIZATION AND TESTING. Elwahidi, L; Abbas-Egabriya, H; Braun, T; Amir, A; Haberman, Y. Gastroenterology. 2025; 169(1):s-249.

Su1960: MULTI-OMICS ANALYSIS OF CROHN’S DISEASE TRAJECTORY FROM ACTIVE TO REMISSION REVEALS THAT DURING REMISSION, ALTERED ILEAL ANTI-BACTERIAL EPITHELIAL SIGNALS AND PATHOGENIC MICROBIOME AND METABOLOMICS PERSIST DESPITE NORMALIZING ILEAL IMMUNE SIGNALS. Haberman, Y; Braun, T; Levhar, N; Efroni, G; Hadar, R; Jessulalevy, D; Asher, AT; Ungar, B; Picard, O; Yablecovitch, D; Kopylov, U; Denson, LA; Eliakim, R; Ben-Horin, S; Amir, A. Gastroenterology. 2025; 169(1):s-908-s-909.